• Nominations Open

  • GAPNA 40th AnniversaryGAPNA’s anniversary theme “Preserve the Past, Enhance the Present, and Secure the Future,” reflects our shared vision for gerontological advanced practice nursing.

     

    Learn How You Can Help

  • FREE CE for GAPNA MembersFREE continuing education credit is available for the following session:

    "The Gerontological Patient in the Emergency Department"

    (session captured at the GAPNA 2020 Annual Conference)


    For January/February 2021 - Get Your Free CNE Now!

  • CoronaCoronavirus (COVID-19) Resources

    In an effort to support our members with the most updated information on COVID-19 we developed this resource page to easily access current CDC information and other resources to assist you professionally and personally.

    We will continue to update this page with more information as it becomes available and welcome your input as we navigate through this situation. As health care professionals it is our job to educate our patients and families on prevention and the what to do if someone is symptomatic.

    View resources

     

Current Strategic Partners

GAPNA is a name chosen to reflect the diversity of our current and potential members, all who are interested in providing the highest quality of care to older adults.

We are the only advanced practice nursing organization that focuses on older adults, the fastest growing segment of the population.

View complete details about the GAPNA Strategic Partners Program.

If you would like to discuss your involvement and more details, please contact Jack Edelman, Director of Marketing, at 856-256-2313, Jack.Edelman@ajj.com or Heidi Perret, Marketing Coordinator, at 856-256-2375, heidi.perret@ajj.com.

GAPNA thanks our current Strategic Partners for their support of our organization.

Platinum Strategic Partners

Avanir Pharmaceutical

Avanir Pharmaceuticals
30 Enterprise, Suite 400
Aliso Viejo, CA 92656
949-389-6700

Avanir Pharmaceuticals is a pharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.

Eisai

Eisai
6611 Tributary Street, Suite 1
Baltimore, MD  21224
410-631-6300
www.eisai.com

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.

LILLY USA, LLC
893 Delaware Street
Indianapolis, IN  46225
800-545-5979
www.lilly.com

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Gold Strategic Partners

Urovant Sciences
5281 California Avenue
Irvine, CA 92617
833-876-8268
infor@urovant.com
www.urovant.com

Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. We exist to advance patient care through bold innovation, with the goal of becoming the leading specialty company recognized and trusted by patients and providers for our commitment to urology. Urovant Sciences, a subsidiary of Sumitomo Dainippon Pharma Co., Ltd., intends to develop novel treatments for additional urologic diseases. Learn more about us at www.urovant.com.

Strategic Partners

ACADIA

ACADIA Pharmaceuticals
3611 Valley Centre Drive, Suite 300
San Diego, CA  92130
www.acadia-pharm.com

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders.

Sunovion
84 Waterford Drive
Marlborough, MA  01752
508-481-6700
www.sunovion.us

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. Our spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives.  

With patients at the center of everything we do, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.

Sunovion’s Long-Term Care team works to support a patient- and caregiver-centric approach across the post-acute continuum of care at all sites of care. This process includes matching the customers Population Health Goals with our Therapeutic Portfolio and other resources to improve the quality of life for the populations we serve. Our ultimate objective is to always be a “Trusted Partner in Post-Acute and Long-Term Care.”

Xeris

Xeris Pharmaceuticals, Inc.
180 N. Lasalle Street, Suite 1600
Chicago, IL  60601
844-445-5704
www.xerispharma.com

 

Xeris Pharmaceuticals, Inc., the maker of Gvoke Hypopen®, is dedicated to unlocking the potential of glucagon. We believe that easier-to-use medicines can have a profound impact on the lives of patients and their families. That is why our first products to market are liquid glucagon, but that is just the beginning. We are also studying how our formulation technology can impact patients with other conditions. We have a persistent drive to pursue advancements that have the potential to change lives. Get to know us and see how our technology is unlocking the potential of today’s medicines at www.xerispharma.com.

GAPNA Sponsor

SOLIQUA

Janssen

Smith & Nephew

Sunovion